8-K filed Jul 23, 2026 at 07:00 ET
Novocure reported Q2 2026 net revenues of $183.6M (+16% YoY), beating consensus of $172.4M, and a GAAP EPS loss of $0.13, significantly beating the consensus estimate of -$0.33. The company raised its full-year 2026 revenue guidance to $710M-$725M (from $690M-$710M) and its Adjusted EBITDA guidance to $0M-$15M (from -$15M-$0M), driven by record active patient growth of 18% YoY and strong adoption of Optune Pax (285 active patients, up from 83 in Q1). The net loss narrowed sharply to $15.7M from $40.1M in the prior year, and the company achieved positive Adjusted EBITDA of $10.8M, a key milestone on its path to profitability. This is a clear beat on both top and bottom lines with raised guidance, indicating accelerating commercial momentum and improving operating leverage.